Latent TB Testing Market Report 2026 With Analyst Recommendations - Amplify Technological Advancement In Diagnostic Laboratories / Increase The R&D Spending To Improve The Efficacy Of Testing Rates

(MENAFN- GlobeNewsWire - Nasdaq) The latent TB testing market presents opportunities through government support, tech advances in multiplex and molecular diagnostics, POC testing, telemedicine, and personalized medicine. These innovations enhance early detection and management, crucial for controlling TB, especially in high-burden and underserved regions.

Dublin, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The "Latent TB Testing Market (2026 Edition)" report has been added to ResearchAndMarkets's offering.
The report analyses the Latent TB Testing Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom France, Germany, China, South Korea, Australia, Japan, and India).

Latent TB Testing Market is being propelled by government initiatives and policies, rising awareness and education, and technological advancements in testing prevalence of TB, especially in high-burden regions, drives the need for effective latent TB testing. As TB remains a global health concern, early detection and management of latent infections become critical for disease control.
The global latent TB testing market is witnessing a surge in multiplex testing capabilities, enabling simultaneous detection of multiple biomarkers associated with latent and active TB. This innovation reduces diagnostic turnaround times and facilitates comprehensive patient management. Furthermore, advancements in molecular diagnostics, such as polymerase chain reaction (PCR)-based assays, are enabling precise detection of latent TB infections by targeting specific genomic sequences of Mycobacterium tuberculosis. These molecular techniques are especially beneficial for diagnosing latent TB in immunocompromised individuals, such as HIV/AIDS patients, where traditional methods may yield inconclusive results.
Point-of-care (POC) testing is another transformative trend gaining traction in the latent TB testing landscape. Portable and user-friendly POC devices empower healthcare providers to conduct rapid testing in remote and resource-limited settings, addressing accessibility challenges in underserved populations. These advancements are particularly crucial in low-income countries, where the burden of latent TB is disproportionately high. Moreover, the miniaturization of diagnostic platforms and the development of battery-operated devices enhance the feasibility of on-the-ground testing initiatives.
Telemedicine and remote diagnostics are reshaping the latent TB testing ecosystem, driven by the COVID-19 pandemic's emphasis on remote healthcare delivery. Mobile health (mHealth) applications and teleconsultation platforms facilitate virtual screening, symptom monitoring, and follow-up care, reducing the need for in-person visits. This trend not only enhances patient convenience but also expands the reach of TB control programs to geographically dispersed populations.
Furthermore, the latent TB testing market is experiencing a paradigm shift towards personalized medicine, with advancements in genomics and proteomics paving the way for tailored diagnostic and therapeutic approaches. Biomarker-based tests and pharmacogenomic profiling are enabling precise risk stratification and individualized treatment plans, thereby improving patient outcomes and reducing the risk of latent TB progressing to active disease. Additionally, ongoing research into novel biomarkers and immune response pathways promises to unlock further innovations in latent TB diagnostics.
Moreover, the global latent TB testing market is undergoing a profound transformation driven by technological advancements and emerging trends. The integration of next-generation diagnostic tools, automation, AI, POC testing, multiplex capabilities, molecular diagnostics, telemedicine, and personalized medicine underscores the industry's commitment to combating latent TB through innovative and accessible solutions. These developments not only enhance the effectiveness of latent TB control programs but also contribute to the broader goal of eradicating tuberculosis as a global public health threat.
Key Topics Covered:
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Analyst Recommendations
2.1 Amplify the incorporation of technological advancement in diagnostic laboratories
2.2 Increase the R&D spending to improve the efficacy of testing rates
3. Global Latent TB Testing Market: Historic and Forecast
3.1 Impact Analysis of Macro Economic Factors on Global Latent TB Testing Market
3.2 Epidemiology: Global Latent TB Prevalence
3.3 Epidemiology: Global Tuberculosis Prevalence
3.4 Epidemiology: Global Tuberculosis Incidence
3.5 Global Latent TB Testing Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
3.6 Global Latent TB Testing Market Segmentation: By Test Type
3.6.1 Global Latent TB Testing Market, By Test Type Overview
3.6.2 Global Latent TB Testing Market Attractiveness Index, By Test Type
3.6.3 Global Latent TB Testing Market Size, By Tuberculin Skin Test (TST), By Value, 2020H-2030F (USD Million & CAGR)
3.6.4 Global Latent TB Testing Market Size, By Interferon Gamma Released Assay (IGRA), By Value, 2020H-2030F (USD Million & CAGR)
3.7 Global Latent TB Testing Market Segmentation: By End User
3.7.1 Global Latent TB Testing Market, By End User Overview
3.7.2 Global Latent TB Testing Market Attractiveness Index, By End User
3.7.3 Global Latent TB Testing Market Size, By Diagnostic Laboratories, By Value, 2020H-2030F (USD Million & CAGR)
3.7.4 Global Latent TB Testing Market Size, By Hospitals and Clinics, By Value, 2020H-2030F (USD Million & CAGR)
3.7.5 Global Latent TB Testing Market Size, By Academic and Research Institute, By Value, 2020H-2030F (USD Million & CAGR)
4. Latent TB Testing Market, Region Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot
Companies Featured

• QIAGEN
• Sanofi
• Abbott Laboratories
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories
• BioMerieux
• Becton Dickinson and Co
• Serum Institute of India
• PerkinElmer Inc.
• LIONEX GmbH

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN17022026004107003653ID1110752364